Search Results - "Ang YLE"

Evaluation of ex vivo drug combination optimization platform in recurrent high grade astrocytic glioma: An interventional, non-randomized, open-label trial protocol.

Authors: Toh TB Thng DKH Bolem N et al.

Source: PloS one [PLoS One] 2024 Jul 26; Vol. 19 (7), pp. e0307818. Date of Electronic Publication: 2024 Jul 26 (Print Publication: 2024).

Publication Type: Journal Article; Clinical Trial Protocol

Journal Info: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE

Drug–drug interactions between epidermal growth factor receptor tyrosine kinase inhibitors and rivaroxaban in vitro and in vivo.

Authors: Wang, Dongxu Wang, Shuanghu Wu, Hualan et al.

Source: PLoS ONE. 6/3/2025, Vol. 20 Issue 6, p1-14. 14p.

Opportunities and challenges in the development of evolving EGFR inhibitors to overcome EGFR TKIs resistance.

Authors: Chen Y Liu QP Yang SJ et al.

Source: Acta pharmacologica Sinica [Acta Pharmacol Sin] 2026 Jul 08. Date of Electronic Publication: 2026 Jul 08.

Publication Type: Journal Article; Review

Journal Info: Publisher: Nature Publishing Group Country of Publication: United States NLM ID: 100956087 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1745-7254 (Electronic) Linking ISSN: 16714083 NLM ISO Abbreviation: Acta Pharmacol Sin Subsets: MEDLINE

EGFR plus MET Targeted Therapies for Overcoming Treatment Resistance in EGFR-Mutant Non-Small Cell Lung Cancer: A Case Report.

Authors: Martínez-Hernandez, Maria F. Lara-Mejía, Luis Izquierdo-Tolosa, Carlos et al.

Source: Oncology Research & Treatment. 2024, Vol. 47 Issue 12, p616-623. 7p.

The impact of EGFR T790M mutation status following the development of Osimertinib resistance on the efficacy of Osimertinib in non‐small cell lung cancer: A meta‐analysis.

Authors: Guo, Liuxian Zhou, Guojin Huang, Min et al.

Source: Clinical Respiratory Journal. Apr2024, Vol. 18 Issue 4, p1-14. 14p.

Advancing breast cancer and lung cancer screening: Expert perspectives to advance programmes in Singapore.

Authors: Tan, Clive Tan, Ern Yu Tan, Geak Poh et al.

Source: Annals of the Academy of Medicine, Singapore. Aug2025, Vol. 54 Issue 8, p498-504. 7p.

Impact of EGFR mutation subtypes and TKI generations on clinical outcomes in lung adenocarcinoma patients with brain metastases treated with gamma knife radiosurgery.

Authors: Roh H Park C Kim W et al.

Source: Journal of neuro-oncology [J Neurooncol] 2025 Dec; Vol. 175 (3), pp. 1331-1341. Date of Electronic Publication: 2025 Sep 16.

Publication Type: Journal Article

Journal Info: Publisher: Springer Country of Publication: United States NLM ID: 8309335 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7373 (Electronic) Linking ISSN: 0167594X NLM ISO Abbreviation: J Neurooncol Subsets: MEDLINE

Innovative Nanocarriers of Sorafenib in the Optimisation of Therapeutic Outcome: Challenges and Applications in Breast Cancer.

Authors: Chaurawal N Estrada AR Pors K et al.

Source: AAPS PharmSciTech [AAPS PharmSciTech] 2026 Mar 19; Vol. 27 (3). Date of Electronic Publication: 2026 Mar 19.

Publication Type: Journal Article; Review

Journal Info: Publisher: Springer Country of Publication: United States NLM ID: 100960111 Publication Model: Electronic Cited Medium: Internet ISSN: 1530-9932 (Electronic) Linking ISSN: 15309932 NLM ISO Abbreviation: AAPS PharmSciTech Subsets: MEDLINE

Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer.

Authors: Li, Yufeng Mao, Tianyu Wang, Jing et al.

Source: Cell Communication & Signaling. 4/11/2023, Vol. 21 Issue 1, p1-13. 13p.

Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance.

Authors: Zhang, Tao Qu, Rong Chan, Shingpan et al.

Source: Molecular Cancer. 5/13/2020, Vol. 19 Issue 1, p1-15. 15p. 1 Color Photograph, 1 Chart, 5 Graphs.

Clinical characteristics and MRI based radiomics nomograms can predict iPFS and short-term efficacy of third-generation EGFR-TKI in EGFR-mutated lung adenocarcinoma with brain metastases.

Authors: Qi, Haoran Hou, Yichen Zheng, Zhonghang et al.

Source: BMC Cancer. 3/21/2024, Vol. 24 Issue 1, p1-15. 15p.

EGFR mutations in non-small cell lung cancer: Classification, characteristics and resistance to third-generation EGFR-tyrosine kinase inhibitors (Review).

Authors: Tian, Zhe Cen, Lilan Wei, Feng et al.

Source: Oncology Letters. Aug2025, Vol. 30 Issue 2, pN.PAG-N.PAG. 1p.

Efficacy and safety of furmonertinib in patients with EGFR‑mutant advanced lung adenocarcinoma after failure of multiple lines of therapy: A single‑center retrospective study.

Authors: Zheng, Yumin Lu, Xingyu Dong, Huijing et al.

Source: Oncology Letters. Jul2025, Vol. 30 Issue 1, pN.PAG-N.PAG. 1p.

Antitumoral activity of Amazon plant species: extracts of Apuleia leiocarpa induce apoptosis and autophagy in lung tumor cell line.

Authors: Vieira de Azevedo, Samir da Silva Ribeiro, Rachel Oliveira da Paixão, Isabel et al.

Source: Rodriguésia. 2024, Vol. 75, p1-14. 14p.

Addition of angiogenesis inhibitors to CDK4/6 inhibitors and fulvestrant in hormone receptor-positive, HER2-negative advanced breast cancer.

Authors: Zhang M Niu L Lyu H et al.

Source: Chinese medical journal [Chin Med J (Engl)] 2026 Jul 07. Date of Electronic Publication: 2026 Jul 07.

Publication Type: Journal Article

Journal Info: Publisher: Chinese Medical Association ; produced by Wolters Kluwer Country of Publication: China NLM ID: 7513795 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2542-5641 (Electronic) Linking ISSN: 03666999 NLM ISO Abbreviation: Chin Med J (Engl) Subsets: MEDLINE

Design and development of mutant EGFR inhibitors from a structural perspective.

Authors: Heppner, David E.¹ davidhep@buffalo.edu

Source: Indian Journal of Biochemistry & Biophysics. Sep2023, Vol. 60 Issue 9, p645-650. 6p.

Radionuclide-based theranostics — a promising strategy for lung cancer.

Authors: Zhu, Tianxing Hsu, Jessica C. Guo, Jingpei et al.

Source: European Journal of Nuclear Medicine & Molecular Imaging. Jul2023, Vol. 50 Issue 8, p2353-2374. 22p. 2 Diagrams, 2 Charts.

Efficacy of lenvatinib and transarterial chemoembolization combination therapy in patients with hepatocellular carcinoma administered an insufficient dose of early lenvatinib.

Authors: Promsorn, Panuwat Yamaguchi, Takashi Kosaka, Hisashi et al.

Source: Molecular & Clinical Oncology. Sep2024, Vol. 21 Issue 3, pN.PAG-N.PAG. 1p.

The Role of CEP55 Expression in Tumor Immune Response and Prognosis of Patients with Non-small Cell lung Cancer.

Authors: Haiyin Fan Jin Zhang Bin Zou et al.

Source: Archives of Iranian Medicine (AIM). Jul2022, Vol. 25 Issue 7, p432-442. 11p.

Exosomes derived from M2 type tumor-associated macrophages promote osimertinib resistance in non-small cell lung cancer through MSTRG.292666.16-miR-6836-5p-MAPK8IP3 axis.

Authors: Wan, Xiaoying Xie, Boxiong Sun, Hui et al.

Source: Cancer Cell International. 2/15/2022, Vol. 22 Issue 1, p1-16. 16p.